manidipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium channel blockers, nifedipine derivatives	1631	89226-50-6

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

manidipine dihydrochloride
manidipine
(+/-)-Manidipine
franidipine
manidipine hydrochloride
manidipine HCl

Molecular weight: 610.71
Formula: C35H38N4O6
CLOGP: 7.02
LIPINSKI: 2
HAC: 10
HDO: 1
TPSA: 114.25
ALOGS: -5.79
ROTB: 12

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyponatraemia	63.19	37.07	27	549	111873	63376573

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	73.87	37.61	53	799	225893	34730186
Trichoglossia	61.38	37.61	10	842	318	34955761
Dermatitis bullous	43.75	37.61	13	839	6909	34949170

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	94.27	29.99	72	1495	415111	79327710
Hyponatraemia	87.23	29.99	50	1517	177798	79565023
Acute kidney injury	59.10	29.99	61	1506	519343	79223478
Trichoglossia	56.54	29.99	10	1557	649	79742172
Dermatitis bullous	37.23	29.99	13	1554	14232	79728589

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C08CA11	CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives
ATC	C09BB12	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and calcium channel blockers
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.7	Basic
pKa2	2.87	Basic
pKa3	2.2	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Voltage-gated L-type calcium channel	Ion channel	Q01668 Q13936	CAC1D_HUMAN CAC1C_HUMAN	BLOCKER				SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Cruzipain	Enzyme		CYSP_TRYCR		IC50	5.22		CHEMBL

External reference:

ID	Source
D01553	KEGG_DRUG
C0065656	UMLSCUI
CHEBI:31800	CHEBI
CHEMBL1085699	ChEMBL_ID
DB09238	DRUGBANK_ID
C054218	MESH_SUPPLEMENTAL_RECORD_UI
11739	IUPHAR_LIGAND_ID
6300	INN_ID
89226-75-5	SECONDARY_CAS_RN
6O4754US88	UNII
4008	PUBCHEM_CID
259487	RXNORM
008164	NDDF
008165	NDDF
765322004	SNOMEDCT_US
765323009	SNOMEDCT_US

Pharmaceutical products:

None